Lumryz
These highlights do not include all the information needed to use LUMRYZ™ safely and effectively. See full prescribing information for LUMRYZ. LUMRYZ (sodium oxybate) for extended-release oral suspension, CIIIInitial U.S. Approval: 2002
10e5e40c-52f3-4c73-8a34-2c29c690a934
HUMAN PRESCRIPTION DRUG LABEL
Jun 7, 2023
Avadel CNS Pharmaceuticals, LLC
DUNS: 117441358
Products 4
Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.
sodium oxybate
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (1)
sodium oxybate
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (1)
sodium oxybate
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (1)
sodium oxybate
Product Details
FDA regulatory identification and product classification information